You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
An upcoming trial by Johnson & Johnson that includes a key drug from this tiny drugmaker could eventually reward investors.
Johnson & Johnson's (JNJ 0.01%) decision to launch a mid-stage study evaluating a slate of hepatitis C drugs that includes Achillion Pharmaceuticals' (ACHN) ACH-3102 could lead to a best-in-class hepatitis C therapy down the road.
In the following slideshow, I outline what you need to know about this trial and why it matters to Achillion Pharmaceuticals' investors.
Todd Campbell owns shares of ACHILLION PHARMACEUTICALS, INC. and Gilead Sciences. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
